Actinium Pharmaceuticals Highlights Presence at the Society of Hematologic Oncology 2017 Annual Meeting
13 sept. 2017 07h30 HE
|
Actinium Pharmaceuticals
- Company’s Actimab-A and Actimab-M programs to be presented at the conference NEW YORK, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc (NYSE American:ATNM) (“Actinium” or “the...
Innovate Biopharma’s Pediatric Ulcerative Colitis Drug Granted FDA Orphan Designation
06 sept. 2017 17h06 HE
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory...
Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017
23 août 2017 09h05 HE
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that four abstracts related to clinical study...
Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Boston Oncology Insights Summit on August 16-17, 2017
09 août 2017 07h30 HE
|
Actinium Pharmaceuticals
NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
02 août 2017 16h05 HE
|
Actinium Pharmaceuticals
Actinium raised total gross proceeds of $16.125 million NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a...
Ocera Therapeutics Reports Second Quarter 2017 Financial Results
01 août 2017 16h05 HE
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on the development...
Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
28 juil. 2017 09h10 HE
|
Actinium Pharmaceuticals
NEW YORK, July 28, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ET
13 juil. 2017 07h00 HE
|
Actinium Pharmaceuticals
- Webinar topics will cover FDA Advisory Panel on Mylotarg, developments with other CD33 targeted therapies and update on Actimab-A - Webinar to be led by Dr. Joseph Jurcic, Director of Hematologic...
Actinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Highlighting Accomplishments and Significant Value Enumerating Catalysts Over the Coming Quarters
15 juin 2017 08h30 HE
|
Actinium Pharmaceuticals
- Iomab-B Phase 3 SIERRA trial enrollment is accelerating as the number of clinical trial sites increase, competitive position as only induction and conditioning regimen remains unchallenged -...
Actinium Pharmaceuticals Announces Appointment of Nitya Ray, Ph.D. as Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain and Other Key Hires in its Product Development and Manufacturing Teams
15 juin 2017 07h00 HE
|
Actinium Pharmaceuticals
- Dr. Nitya Ray joins Actinium Executive Team with 30 years of radiopharmaceutical and biologics product development, manufacturing and strategic planning experience - Also announced is the recent...